Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.50 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944099 | 0.87 | RAB9A (0.50) | KMT2ARAB9ANPC1CYP1A2TDP1 | |
| SCHEMBL9944087 | 0.87 | RAB9A (0.52) | KMT2ARAB9ANPC1CYP1A2TDP1 | |
| SCHEMBL9944115 | 0.86 | KMT2A (0.58) | KMT2ARAB9ANPC1CYP1A2TDP1 | |
| SCHEMBL1459226 | 0.83 | NR1H4 (0.46) | KMT2ARAB9ANPC1CYP1A2TDP1 | |
| SCHEMBL1459379 | 0.82 | MAPT (0.53) | KMT2ARAB9ANPC1TDP1SMN1; SMN2 | |
| SCHEMBL9944083 | 0.82 | NPC1 (0.50) | KMT2ARAB9ANPC1CYP1A2TDP1 | |
| SCHEMBL9944088 | 0.81 | NPC1 (0.53) | KMT2ARAB9ANPC1CYP1A2TDP1 | |
| SCHEMBL1458488 | 0.80 | RAB9A (0.49) | KMT2ARAB9ANPC1CYP1A2TDP1 | |
| SCHEMBL9944150 | 0.80 | MAPT (0.54) | KMT2ARAB9ANPC1TDP1NR1H4 | |
| SCHEMBL1458178 | 0.79 | MAPT (0.56) | KMT2ARAB9ANPC1NR1H4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447028-B2 | Therapeutic aryl-amido-aryl compounds and their use | KING'S COLLEGE LONDON (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | KMT2A 1418/4885RAB9A 271/4885NPC1 277/4885 |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | KMT2A 1418/4885RAB9A 271/4885NPC1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.